TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of cluster headache attacks with pain reduced to mild or none
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eosinophil counts in airway mucosal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Operative room occupancy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the expression of autophagy genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with a clinically significant electrolyte disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of monthly heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospital course
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AUC(0-¥) and Cmax of GSK1278863A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Artery Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of validated respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: EPA concentrations in plasma lipids and red blood cell lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage increase in skilled Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of stakeholders accepting CORN intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Capillary Transit Time Heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASEBA Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of passes with Describe patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease activity index 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease activity index 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the bacterial composition (Bacterial microbiome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gene expression in the nasal lining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress-hormone axis reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants for surgical repair of CHD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Unplanned re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: interface pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with non-ulcerative recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Arthritis relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of abstinence following the programmed lapse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Confirmed Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sexual Dysfunction Rate Reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ophthalmic DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Main Symptom Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: H2O clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed graft function: Dialysis requirement during the first week after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the curve (AUC) GPT (ALT) after transplantation during 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mask Seal Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mask Seal Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RECIST response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Ratings of Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Comfort Preference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in appropriate aspirin prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in clinical performance on blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in clinical performance on cholesterol management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in clinical performance on smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of at least one relapse
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale III&IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Varicella zoster specific immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ppo FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ppo DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetic parameters for teriflunomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients developing sensory-neural hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 7-day point prevalence quit rate at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of molar distalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of liver-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resident Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residence Confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary Excretion of Alendronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood flow velocity change in middle cerebral artery (MCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortical brain oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of NOM
Endpoint domain: Adverse events/effects
Primary endpoint: sustained tachycardia/ventricular fibrillation or sudden cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute pyelonephritis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Histological lesion clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of Gastric Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cessation of smokeless tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical in-stent acute lumen gain in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ratio of stent expansion index (SEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of the extraction socket
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eosinophils/mL in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: wall to lumen ratio of retinal arterioles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to Premature Treatment Discontinuation Due to Any Reason
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Sustained Virologic Response (SVR) at 12 Weeks or Later After Completion of the Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profile of mood states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anthocyanin levels in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycemic response attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: depression (PHQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hours Per Week of Paid Work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: rate of ventriculo-peritoneal malfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rate of ventricle-peritoneal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Low frequency (LF) spectral analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance covered in six-minute walk tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sentinel lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visualisation of gastrointestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: changes in positive and negative scale score (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in binary betweenness centrality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of ethinyl estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of participants with complete remission (CR)/CR with incomplete recovery (CRi) with adequate blood count recovery (ABCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Anterior Trunk Displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by laboratory evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with hypoxic ischaemic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Influence of risk factors on sarnat staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of serum hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive delay
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total number of periods of carbohydrate supplementation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fear of death and dying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Needs and wishes at the end-of-life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in dimension of the alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated hemoglobin (A1C) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight (body mass index [BMI]) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes medication reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Foot Strike Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-Year Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Duration of oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: O2 concentration until Downes' score less than 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anterior Cruciate Ligament Quality of Life (ACL-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Central Aortic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative patient controlled morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of GLPG0634 and metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of depression diagnoses
Endpoint domain: Mortality/survival
Primary endpoint: Recommended phase 2 dose (RP2D) based on Dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Five Times Sit to Stand Test (5xSTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who develop grades III/IV Bearman regimen-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-from-baseline in individual corrected QTc (ΔQTcI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of fibrosis in thyroid tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Measured level of anti-tTG levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of newly identified HIV infections
Endpoint domain: Mortality/survival
Primary endpoint: area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration-time curve during steady state (AUC(0-τ))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the concentration of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in the concentration of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in the concentration of pyruvate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in the concentration of glycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Six-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety / Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma level of neutrophil gelatinase-associated lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-PRK pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Comfortable Contact Lens Daily Wear Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gout flare frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decision to proceed to full RCT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month infant mortality
Endpoint domain: Mortality/survival
Primary endpoint: rate of major cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response of Hemangioma to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with extracapsular extension and seminal vesicle involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Days to engraftment of absolute neutrophils and platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of non-engraftment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of secondary graft failure
Endpoint domain: Adverse events/effects
Primary endpoint: HIV antibody testing uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of lumen opened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volumetric bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical porosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative venous thromboembolic event
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of dysphagia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Regenerated Bone Gain (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Patient Activation at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Activation at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Serum Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Global Impression of Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in plasma MK-7 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent changes in intact Parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement on the Global Aesthetic Improvement Scale (GAIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensation of abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: major cardiac or cerebrovascular event (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of acute lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of acute respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Score performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of BI 836909
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photodamage severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concomitant Medications
Endpoint domain: Adverse events/effects
Primary endpoint: Insomnia occurrence
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mutation in NOTCH1 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cardiac troponin I (cTnI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in physiological resiliency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes